Syed Zaidi, MD
Psychiatry · Friendswood, TXNPI 1932549250
Payments from drug & device makers
Across 285 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Boehringer Ingelheim$1K
- Johnson & Johnson$583
- Alkermes, Inc.$514
- Teva Pharmaceuticals USA, Inc.$450
- AbbVie$312
- plus $2K from 22 others
What the payments were for
- Travel & lodging$1,02216%
- Food & beverage$5,22184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 60 | $1,208 |
| Boehringer Ingelheim | 4 | $1,122 |
| Johnson & Johnson | 32 | $583 |
| Alkermes, Inc. | 24 | $514 |
| Teva Pharmaceuticals USA, Inc. | 30 | $450 |
| AbbVie | 30 | $312 |
| Otsuka America Pharmaceutical, Inc. | 14 | $226 |
| Vanda Pharmaceuticals Inc. | 11 | $222 |
| Avanir Pharmaceuticals, Inc. | 12 | $216 |
| Indivior Inc. | 13 | $210 |
| Abiomed | 1 | $186 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $167 |
| Sunovion Pharmaceuticals Inc. | 11 | $158 |
| Acadia Pharmaceuticals Inc | 6 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| UCB, Inc. | 4 | $103 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Noven Therapeutics, LLC | 3 | $39 |
| Lundbeck LLC | 2 | $37 |
| Neos Therapeutics, LP | 1 | $27 |
| SK Life Science, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$480
- INGREZZA$214
- ARISTADA INITIO$120
How this compares
$6,242 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 164 | $539,281 |
| IngrezzaValbenazine Tosylate | 16 | $118,382 |
| Abilify MaintenaAripiprazole | 24 | $71,354 |
| AristadaAripiprazole Lauroxil | 21 | $71,206 |
| Risperdal ConstaRisperidone Microspheres | 32 | $52,686 |
| EliquisApixaban | 39 | $23,260 |
| Divalproex Sodium | 573 | $20,643 |
| Aripiprazole | 422 | $19,781 |
| Olanzapine OdtOlanzapine | 85 | $18,535 |
| JardianceEmpagliflozin | 25 | $15,609 |
| Paliperidone ErPaliperidone | 57 | $15,440 |
| Memantine Hcl | 417 | $13,506 |
| Trazodone Hcl | 921 | $11,633 |
| Chlorpromazine Hcl | 36 | $10,487 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $10,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Xarelto | $583 | $599,101208 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,208 | $118,38216 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $226 | $71,35424 claims |
| Alkermes, Inc.Aristada | $514 | $71,20621 claims |
| Boehringer IngelheimJardiance | $1,122 | $15,60925 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $450 | $2,45315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Friendswood
- Napoleon HigginsFriendswood$1.1M
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.